GP Vivas · mental-health
Anxiety disorders — structured viva
Structured oral on anxiety disorders: differentiating GAD, panic and social anxiety, defending GAD-7 bands with Cochrane accuracy data, arguing the stepped-care ladder and sertraline-first pharmacotherapy, handling benzodiazepine pressure, and closing on measurement-based relapse prevention.
On this page
Study tools
Target exams
Stem
You are the GP. Anxious presentations fill the morning list; the registrar asks why each one needs its own pathway. [1]
Branch A — Classification that changes treatment
Examiner: Are GAD, panic and social anxiety really different diseases? [1]
Strong answer: They are distinct symptom syndromes with shared first-line treatments. GAD: excessive, hard-to-control worry across domains more days than not for at least six months. Panic disorder: recurrent unexpected discrete attacks plus concern about attacks or avoidance. Social anxiety: fear of scrutiny with avoidance. Specific phobia and agoraphobia differ by trigger. The WFSBP guideline evaluated over 1000 RCTs across these conditions and converged on one message — SSRIs/SNRIs first-line drugs, CBT first-line psychotherapy — which is precisely why the grouping matters less than matching the right modality to severity and preference. [1]
References17ShowHide
- [2]Spitzer RL, Kroenke K, Williams JB et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine, 2006.PMID 16717171
- [3]Aktürk Z, Hapfelmeier A, Fomenko A et al. Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults. The Cochrane database of systematic reviews, 2025.PMID 40130828
- [4]Slee A, Nazareth I, Bondaronek P et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet, 2019.PMID 30712879
- [5]Lewis G, Duffy L, Ades A et al. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA). The lancet. Psychiatry, 2019.PMID 31543474
- [6]Cardoner N, Gutiérrez-Rojas L, Saiz P et al. Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness. Frontiers in pharmacology, 2025.PMID 39989902
- [7]Kong W, Deng H, Wan J et al. Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials. Frontiers in pharmacology, 2020.PMID 33343351
- [9]Matsumoto K, Hamatani S, Shimizu E Effectiveness of Videoconference-Delivered Cognitive Behavioral Therapy for Adults With Psychiatric Disorders. Journal of medical Internet research, 2021.PMID 34898445
- [10]Farris SG, Derby L, Kibbey MM Getting comfortable with physical discomfort: A scoping review of interoceptive exposure in physical and mental health conditions. Psychological bulletin, 2025.PMID 40014537
- [12]Lewis G, Marston L, Duffy L et al. Maintenance or Discontinuation of Antidepressants in Primary Care. The New England journal of medicine, 2021.PMID 34587384
- [13]Krijnen-de Bruin E, Scholten W, Muntingh A et al. Psychological interventions to prevent relapse in anxiety and depression: A systematic review and meta-analysis. PloS one, 2022.PMID 35960783
- [14]Remes O, Brayne C, van der Linde R et al. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain and behavior, 2016.PMID 27458547
- [16]Nascimento AOD, Silva CECD, Silva MLD et al. The Effects of Caffeine on Anxiety Behavior in Healthy Individuals: A Systematic Review of the Literature. Stress and health, 2026.PMID 41549915
- [17]Struijs SY, de Jong PJ, Jeronimus BF et al. Psychological risk factors and the course of depression and anxiety disorders: A review of 15 years NESDA research. Journal of affective disorders, 2021.PMID 34706448
- [18]García Álvarez Á, Riera Serra P, Ricci-Cabello I et al. Effectiveness and safety of focused deprescribing interventions targeting specific drug classes in older adults across clinical settings. Age and ageing, 2026.PMID 42607278
- [8]Zainal NH, Soh CP, Van Doren N et al. Do the effects of internet-delivered cognitive-behavioral therapy (i-CBT) last after a year and beyond? A meta-analysis of 154 randomized controlled trials (RCTs). Clinical psychology review, 2024.PMID 39579466
- [15]Remes O, Wainwright N, Surtees P et al. Generalised anxiety disorder and hospital admissions: findings from a large, population cohort study. BMJ open, 2018.PMID 30368445
- [1]Bandelow B, Allgulander C, Baldwin DS et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2023.PMID 35900161